A Study Evaluating the Diagnostic Yield and Safety of the ProCore vs Conventional EBUS-TBNA Needle in Subjects With Suspected Sarcoidosis

Sarcoidosis Clinical Trial

Official title:

A Study Evaluating the Diagnostic Yield and Safety of the ProCore vs Conventional EBUS-TBNA Needle in Subjects With Suspected Sarcoidosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03656003
• Other study ID #: Int/IEC/2018/00169
• Status: Completed
• Phase: N/A
• Start date: August 1, 2018
• Est. completion date: July 31, 2019

Study information

• Verified date: February 2021
• Source: Postgraduate Institute of Medical Education and Research
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the yield and safety of two different needles for performing endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) in patients with sarcoidosis. The two needles that will be compared will be the 22-gauge ProCore needle and the conventional 22-gauge EBUS-TBNA needle.

Description:

Sarcoidosis is a multisystem disorder of unknown cause characterized by granulomatous inflammation involving various organ systems. The diagnosis is made on the basis of a suggestive clinicoradiological picture, histopathologic evidence of non-caseating granuloma, and exclusion of other known causes for granulomatous inflammation. As the lung and mediastinal lymph nodes are the most commonly involved structures in sarcoidosis, various bronchoscopic techniques like endobronchial biopsy (EBB), transbronchial biopsy (TBLB) and transbronchial needle aspiration (TBNA) are needed for tissue sampling.

Among the bronchoscopic techniques, TBNA of lymph nodes is a useful modality especially when combined with endobronchial and transbronchial biopsies. The efficacy and safety of conventional TBNA are well established. With the advent of endobronchial ultrasound (EBUS) in the last decade, this new technology has been widely used to guide transbronchial needle aspiration. The technique is minimally invasive and offers the additional advantage of choosing the appropriate node for sampling based on the vascularity, echogenicity and size. Studies subsequently have demonstrated the superiority of EBUS-TBNA over conventional TBNA.

As EBUS-TBNA is the standard procedure now for accessing intrathoracic lymph nodes, the technical aspects of the procedure need further investigation. Several aspects have been studied to optimize the yield including the number of aspirations or passes required per lymph node station, needle gauge (21 vs. 22 gauge), suction pressure, and the distance travelled by the needle within the lymph node.

The EchoTip ProCore High Definition ultrasound biopsy needle (Cook Medical Inc., Bloomington, Ind., USA) is a novel needle that has been used mainly in sampling intra-abdominal lesions. It has a special bevel which allows a core biopsy along with aspiration of the lymph node material. In case of mediastinal lymph node enlargement due to malignancy, needle aspiration alone may yield sufficient material to identify malignant cells. However, in sarcoidosis, the core biopsy specimen obtained with the ProCore needle may potentially increase the identification of granulomas. The investigators hypothesize that the 22-gauge ProCore needle will have a higher yield in diagnosing intrathoracic lymphadenopathy due to sarcoidosis as compared to the conventional 22-gauge EBUS-TBNA needle. In this study, the investigators plan to evaluate the yield and safety of the 22-gauge ProCore needle as compared to the conventional 22-gauge EBUS-TBNA needle in patients with sarcoidosis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: July 31, 2019
• Est. primary completion date: July 31, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria: Patients meeting all the following criteria will be eligible for inclusion in the study:

• Age group of 18 to 75 years

• Clinicoradiological suspicion of sarcoidosis where EBUS-TBNA is being planned

• Enlarged hilar and mediastinal lymph nodes >10 mm (any axis) on computed tomography of the chest

• Ability to provide informed consent to participate in the study

Exclusion Criteria: Patients with any of the following will be excluded:

• Hypoxemia (SpO2 <92% on FiO2 of 0.3)

• Treatment with systemic glucocorticoids for >2 weeks in the preceding three months

• Diagnosis of sarcoidosis possible with another minimally invasive technique such as skin biopsy or peripheral lymph node biopsy

• Failure to provide informed consent

Related Conditions & MeSH terms

• Sarcoidosis

Intervention

Device:
• Procore biopsy needle
EBUS-TBNA with the EchoTip ProCore needle (Cook Medical Inc., Bloomington, Ind., USA)
• Conventional biopsy needle
EBUS-TBNA with the conventional 22-gauge EBUS-TBNA needle (Vizishot, Olympus, Japan)

Locations

Country	Name	City	State
India	Bronchoscopy suite, PGIMER	Chandigarh

Sponsors (1)

Lead Sponsor	Collaborator
Postgraduate Institute of Medical Education and Research

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of patients with sarcoidosis diagnosed by EBUS-TBNA (Diagnostic yield)	The diagnostic yield is defined as the proportion of patients with a final diagnosis of sarcoidosis diagnosed by EBUS-TBNA	6 months
Secondary	Number of patients with adequate EBUS-TBNA aspirate on cytology	Defined as preponderance of lymphocytes or a definite diagnosis (sarcoidosis, tuberculosis or others) on EBUS-TBNA aspirate	2 weeks
Secondary	Incidence of adverse events related to EBUS-TBNA procedure in the two groups	Endobronchial bleeding, pneumothorax, hypoxemia, mediastinitis	1 week